ArticleMetabolic brain disease2026
Sexual dimorphism and photoperiodism in cognitive and neuronal ionic changes in scopolamine-induced cognitive impairment.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photoperiodism and biological sex are factors that may influence cognitive impairments. Scopolamine, a muscarinic acetylcholine receptor antagonist, is a widely used pharmacological tool for modelling cognitive impairments, but its cellular interaction with photoperiodic cycle and sex is poorly understood. This study aimed to evaluate the effects of photoperiodism and sex on neurobehavioural and ionic chnages in scopolamine-induced cognitively-impaired mice. Sixty-four male and female mice (18.5 ± 0.9 g) were assigned to eight groups; four tested during the photophase and four during the scotophase, each comprising normal controls and scopolamine-treated animals of both sexes. Memory was assessed using the elevated plus maze and novel object recognition tests. Spinal tissue ionic concentrations of sodium, potassium and chloride were measured. Control mice outperformed scopolamine-treated mice in memory retention across both phases. Novel object recognition scores were paradoxically lower in controls than in impaired mice during the photophase. Scotophase analysis revealed elevated sodium and chloride levels in impaired mice; while potassium concentrations were specifically raised in scopolamine-treated females during the photophase, pointing to sex-specific changes in neuronal excitability. The findings suggest that photophase and female sex potentiated long-term memory consolidation and may modulate neuronal excitability in scopolamine-induced cognitive impairments. In conclusion, the result shows the need to incorporate photoperiodism and sex as important variables in the interpretation of cognitive impairment and in pre-clinical cognitive research. Overlooking the two factors may mask or misrepresent the true neurobiological effects of pharmacological models of impairment.
Indexed as
Identifiers
42201435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.